Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 10/20 | 0.77 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.77 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.77 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.77 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.77 |
| ▸ | ATIC | P31939 | 3/20 | 0.77 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.77 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.77 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.77 |
| ▸ | FRK | P42685 | 1/20 | 0.77 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL7969 | 1.00 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL6034765 | 1.00 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2549428 | 1.00 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL108860 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124673 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL3388816 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1934793 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL126068 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124663 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15648731 | 0.99 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 62363 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746899-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC | Iovance Biotherapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-12637498-B2 | PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-05-26 | — | — | US | claimed |
| CN-122075411-A | Tripterine liposome, its combined medicine and its application in preventing and treating tumor | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075707-A | Application of ZFP36 serving as target spot in non-small cell lung cancer resistant drug and pharmaceutical composition | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026103822-A1 | COMBINATION OF RAS INHIBITOR AND PD-1 OR PD-L1 INHIBITOR, AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-6686365-B2 | Pharmaceutical composition | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | claimed |
| US-20030212083-A1 | PHARMACEUTICAL COMPOSITION | LILLY FORSCHUNG GMBH (DE) | 2003-11-13 | — | — | US | claimed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| CN-1396828-A | Pharmaceutical composition comprising Pemetrexed together with monothioglycerol L-cystein or thioglycolic acid | LILLY CO ELI (US) | 2003-02-12 | — | — | CN | claimed |
| EP-1265612-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL, L-CYSTEIN OR THIOGLYCOLIC ACID | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2002043773-A2 | TISSUE SPECIFIC PRODRUGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2002-06-06 | — | — | WO | claimed |
| CN-1342147-A | Nitrooxyderivatives having anti-inflammatory, analgesic and antithrombotic activity | NICOX SA (FR) | 2002-03-27 | — | — | CN | claimed |
| WO-2001056575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL L-CYSTEIN OR THIOGLYCOLIC ACID | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |